We are very pleased to have settled an agreement with Artemis Bioservices today, which ranked highest in our thorough selection process. Artemis Bioservices' unique combination of specialist knowledge in preclinical HSV-2 models, scientific expertise, and excellent references make them our preferred partner in the development of a therapeutic HSV-2 vaccine.

We are excited to add Artemis Bioservices to our network of partners and look forward to a successful and rewarding collaboration.

Our collaboration with Artemis Bioservices is an important step in strengthening and preparing our preclinical studies for the HSV-2 vaccine.

Through this partnership, we ensure access to valuable expertise and experience, which is crucial for our upcoming studies to maintain the highest possible quality and where we create a robust scientific basis for our HSV-2 vaccine.

We are very pleased to have been selected for Merck’s local European Grant Program and Sponsorship, the grant contributes to our continued work with the development of our innovative vaccine candidates.

...our portfolio will consist of two vaccine candidates against the two most common sexually transmitted diseases, both based on mRNA technology, giving us good opportunities to achieve synergies.

I am truly honored to have been invited by Dr. Martinez Bravo to lecture about DNA and RNA Vaccines at such a prestigious university.

It was a pleasure to share my expertise within the field of vaccinology with young and talented aspiring scientists, and I hope that maybe some of them were inspired to pursue a career in vaccine development.

It is of course gratifying that our Director of Preclinical Development has been invited to lecture at such a highly ranked university as UCL School of Pharmacy as it clearly indicates that Eurocine Vaccines is at the forefront of vaccine development and that our in-house expertise is sought after in the academic world.

mRNA-based vaccines have shown great clinical potential to drive both antibodies and T-cells, which is exactly what we aim for with our chlamydia vaccine. In addition, we see good opportunities to achieve synergies between our portfolio projects which use the same platform technology.

I am overwhelmed by these results.

The T cell responses that we report here are in line with those that can be detected after recovery from an infection and are focused to a part of the HSV-2 virus that we believe is important to target to obtain immunologic control of the virus.

Patents with a commercially relevant protection constitutes a crucial part of our work, onboarding new candidates. The HSV-2 vaccine candidate is no exception, where patents today are approved or pending for major markets worldwide.

We can look back on an intense and evolving fiscal year 2021/2022 for Eurocine Vaccines. The recent development of our innovative vaccine candidate portfolio makes me confident that we are well positioned to improve the quality of life and reduce suffering for millions of patients, an ambitious goal that we now continue working towards into the new fiscal year.

Our work with the chlamydia vaccine candidate is progressing and we are preparing to produce study products for our upcoming toxicology study and to plan the phase I clinical trial in further detail.

In addition to the development of the chlamydia vaccine candidate, much of our work has focused on expanding our portfolio of innovative vaccine candidates. We are therefore very pleased to have completed the financial year with the addition of a therapeutic vaccine candidate against Herpes Simplex Virus type 2, HSV-2, to the vaccine portfolio.

We are excited to add another potent vaccine candidate to our portfolio that holds promise to alleviate suffering and improve quality of life for millions of patients. The next few years will be intense, and we will work relentlessly to this end.

I am very pleased that we have added this promising candidate to our portfolio, especially given the impressive scientific development of the therapeutic vaccine made to this point by Redbiotec.

The candidate is perfectly in line with our portfolio strategy.

We are very content to have engaged Eurocine Vaccines for the leap ahead, taking our novel HSV-2 candidates from innovation towards a potential blockbuster. Eurocine Vaccines has proven to be one of the few vaccine experts who are engaged, committed and able to do just that.

It is a perfect example of when to prevent rather than treat. That is where the vaccine comes in.

The need for modern and effective vaccines is great, not least for such a globally widespread infection as chlamydia. The end of 2021 has been an important period for the continued development of our chlamydia vaccine candidate, which of course motivates us in the continued work of developing a preventive vaccine against chlamydia infection.

We see great potential in the value that Eurocine Vaccines creates, with its chlamydia vaccine candidate and vaccine portfolio under development, which is well in line with Flerie Invest's investment strategy. Together, we contribute to advancing the development of medical innovations that meet important patient needs.

There is a strong need for a safe and effective chlamydia vaccine and the proceeds from TO 4 give us the opportunity to pursue the development of the chlamydia vaccine candidate and the portfolio towards several near-term goals. Flerie Invest's solid background in the life science sector further strengthens Eurocine Vaccines.

We are very pleased by the strong confirmatory findings so far in this project and that we can induce exactly the type of immune response that is considered important for protection against Chlamydia infection.

It is completely in line with our strategy to actively seek additional opportunities to innovatively create added value based on our investments.

Although the market potential is smaller for a diagnostic tool than for a vaccine, it is all about how to best contribute to modern healthcare based on our research and development.

It is exciting times for us when both protein and mRNA-based vaccines may be combined in our portfolio, proving our thorough and broad experience.

It is extremely satisfying to see the rapid and precise work with transferring our know-how in this development project.

Biovian, our selected CDMO, has proven their scientific and technical ability in this area of biologic process development and GMP manufacturing.

We have reached an important milestone by generating the research cell bank for the work to come. Now, the extensive work with developing a quality assured manufacturing process and thorough documentation has begun.

My team and I are thrilled to work at the frontier of advanced drug development with the experts of Eurocine Vaccines.

By optimizing the vaccine candidate, we can focus the immune response so that the antibodies formed bind to relevant parts of the chlamydia bacterium to an even greater extent than before. This is probably of great importance for how effective the vaccine is, which will be studied in future studies.

Now we will move forward with the vaccine candidate and evaluate both the immune response of T cells and protection against infection and disease. It will be very exciting to see to what extent the immune response is converted into protection.

The results confirm that we are on the right track with the vaccine and support the strategy we have chosen for the development - to already at this stage invest in the development of a manufacturing method, suitable for manufacturing on an industrial scale.

This confirmation is an important step ahead of further development of the chlamydia vaccine candidate towards the first clinical study.

It has been an incredibly exciting period for Eurocine Vaccines and we have managed to close very important agreements.

Both we and Biovian are looking forward to the collaboration and the mutual knowledge transfer within biological pharmaceutical production, which is a highly intense area in the development of new pharmaceuticals.

The selection of Biovian means that we can conduct our activities with continuity, since they also have their own GMP facility for the manufacture of products for clinical studies.

The evaluation agreement reaffirms the great interest in our vaccine technology Endocine™ and gives Eurocine Vaccines increased visibility in the global market. The veterinary market for vaccines represents large and worldwide sales and can thus be a significant complement to human vaccines, which are the main focus of Eurocine Vaccines.